Full-Time

MHSU Clinician

Updated on 8/20/2026

Deadline 7/28/27
Fraser Health

Fraser Health

10,001+ employees

Public health authority operating hospitals

Compensation Overview

CA$44.85 - CA$56.02/hr

Chilliwack, BC, Canada

In Person

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Risk Management
Care Coordination

Get referred to Fraser Health

See people who can refer or advise you

Requirements
  • A bachelor's degree in Social Work, Clinical Counselling, or another relevant health-related discipline is required.
  • Two years of recent, related experience working with clients and families with, or affected by, mental illness and substance use disorders, or an equivalent combination of education, training, and experience, is required.
  • Eligibility for registration or membership with the applicable professional association or regulatory body is required.
  • A valid Class V British Columbia driver's licence and access to a personal vehicle for business-related purposes are required.
  • Demonstrated client assessment and case management skills are required.
  • The ability to communicate effectively verbally and in writing, including empathic and respectful communication appropriate to the situation, is required.
  • The ability to network effectively with other services and agencies is required.
  • The ability to set priorities, organize work to manage a heavy and demanding caseload, and exercise sound clinical and non-clinical judgment is required.
  • The ability to work effectively and flexibly manage changing caseload needs under pressure and during times of change is required.
  • The ability to work independently with minimal supervision while seeking appropriate consultation and approval from the Coordinator is required.
  • The ability to maintain appropriate confidentiality in accordance with applicable regional policies is required.
  • The ability to learn new methodologies, ideas, and concepts quickly is required.
  • The ability to provide efficient service while meeting clinical and administrative government and health-region policies, standards, and protocol requirements is required.
  • Knowledge of community resources and methods of accessing them is required.
  • Comprehensive knowledge of emergency triage procedures, mental health status assessment, counseling principles, and interview techniques is required.
  • Working knowledge of psychopharmacology, crisis theory, and de-escalation techniques is required.
  • Working knowledge of DSM-5 Multiaxial Diagnosis or the International Classification of Diseases is required.
  • The physical ability to carry out the duties of the position is required.
Responsibilities
  • Develop and implement recovery-oriented treatment options and plans in collaboration with clients and natural supports.
  • Provide comprehensive case consultation and follow-up support on treatment decisions with interdisciplinary team members.
  • Support the development and maintenance of abilities related to activities of daily living, discharge, and transition of care.
  • Update the Clinical Coordinator on client treatment status and progress, including significant or unusual issues, developments, and circumstances.
  • Provide individual, group, and family support using interviewing, supportive counseling, and assessment methods.
  • Share responsibility for distributed workload, case management, recovery-plan and goal formulation, crisis intervention, home visits, groups, and client outreach.
  • Support intake by gathering client information and history through phone interviews or other methods.
  • Assess client mental health and substance-use status and risk, priority of care, eligibility, resource availability, service priorities, and required level of care.
  • Collaborate with the interdisciplinary team to determine the best approach to care and assess the need for emergent crisis intervention.
  • Facilitate client use of community services and rehabilitative programs by researching and liaising with services and program providers.
  • Assist clients with housing needs and arrangements, provide advice and consultation, and refer clients to appropriate community treatment alternatives and services.
  • Use community resources, volunteers, community groups, alternate care services, and other agencies to develop supportive and rehabilitative programs for adults and their families.
  • Advocate for clients by explaining appeal processes, providing client information to relevant ministries, assisting with forms, and acting as a resource for clients and families.
  • Arrange hospital admissions, including involuntary admissions, by gathering background information, conducting initial assessments, completing forms, and contacting relevant parties.
  • Arrange transportation and transport clients to hospital when required.
  • Provide care linkages between community mental health and substance use services and acute care facilities to support discharge assessment and care planning.
  • Liaise with forensic programs and exchange relevant client information to prepare for continuity of care.
  • Provide individual and group sessions, including psychoeducation and skill-development groups, to clients and families with complex needs.
  • Facilitate client, family, and lived-experience involvement activities, including information sessions.
  • Educate staff, clients, and families about the impact of illness and functional capabilities.
  • Maintain client records, including assessments, charting in PARIS or other clinical information systems, progress notes, and reports, in accordance with standards, policies, procedures, and regulatory requirements.
  • Ensure access to and disclosure of information and records comply with the Freedom of Information Act.
  • Provide follow-up care and referrals to healthcare professionals, including vocational counselors, recreational therapists, occupational therapists, and psychiatrists.
  • Participate in quality-improvement and risk-management activities, provide feedback on program and service gaps, and suggest solutions to maintain a coordinated community care system.
  • Participate in ongoing clinical education and maintain current knowledge of federal and provincial legislation affecting mental health and substance-use care and service delivery.
  • Participate in local committees and advisory boards as a team representative.
  • Inform regional staff, community groups, and agencies about the team's role and function through formal and informal in-services.
  • Participate in clinical research and program-evaluation activities relevant to clients, families, hospitals, and the community.
  • Perform other related duties as assigned.

Fraser Health is a health authority in British Columbia that provides a wide range of medical services to about 1.8 million people. It operates 12 hospitals, including major trauma centres, plus an outpatient care and surgery centre, and offers residential care, home health, public health, and mental health services. The organization employs over 40,000 staff, medical professionals, and volunteers who run clinics, care centres, and community programs. Its goal is to deliver accessible, high-quality care across the network while creating good workplaces for its employees and volunteers.

Company Size

10,001+

Company Stage

Grant

Total Funding

$20K

Headquarters

Surrey, Canada

Founded

2001

Get referred to Fraser Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fraser Health won $1.3 million March 2026 to expand Indigenous elder home care.
  • Royal Columbian Hospital activated March 24, 2026, adding one more clinical-trial site.
  • Surrey’s new UPCC opened January 28, 2026, targeting 64,000 annual patient visits.

What critics are saying

  • Mission Memorial’s ED shut down May 25, 2026, exposing persistent physician staffing gaps.
  • Peace Arch maternity closed for the sixth time in March 2026, signaling brittle coverage.
  • Cloverdale hospital costs reached $2.88 billion, and completion slipped to August 2029.

What makes Fraser Health unique

  • Fraser Health runs 12 hospitals across 20 communities, anchoring Lower Mainland acute care.
  • Its Indigenous-led home-care programs integrate Stó:lō, FNHA, and Métis partners.
  • Fraser Health is deploying AI scheduling with Deloitte and Scale AI across hospitals.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

11%
StockTitan
Mar 24th, 2026
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II cardiac surgery-associated AKI trial.

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II cardiac surgery-associated AKI trial. Rhea-AI Impact Rhea-AI Sentiment Rhea-AI summary. Arch Biopartners (OTCQB: ACHFF) announced a Clinical Trial Agreement with Fraser Health Authority to prepare Royal Columbian Hospital for recruitment in its Phase II trial of LSALT peptide for prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). Royal Columbian Hospital is now the ninth global site activated and the fourth Canadian recruiting site, after Toronto General Hospital, St. Michael's Hospital, and University of Calgary. Positive. * Royal Columbian Hospital received final Research Ethics Board and operational approvals * Royal Columbian Hospital became the 9th global site activated in the Phase II CS-AKI trial * 4 Canadian sites are actively recruiting patients (Toronto General, St. Michael's, Calgary, RCH) Negative. 03/24/2026 - 09:13 AM TORONTO, March 24, 2026 (GLOBE NEWSWIRE) - Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Authority has entered into a Clinical Trial Agreement ("CTA") with Arch to enable the Royal Columbian Hospital (RCH) to begin preparing for the recruitment phase in Arch's ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With the Clinical Trial Application (CTA) completed, RCH has now received final Research Ethics Board and operational approvals, including the final letter of authorization from Fraser Health. RCH will be the ninth site activated globally in the study and will be the fourth site to recruit patients in Canada. Toronto General Hospital, part of University Health Network, St. Michael's Hospital, part of Unity Health Toronto, and the University of Calgary, Cumming School of Medicine, continue to actively enroll new patients into the trial. The Company is currently progressing feasibility and start-up discussions with additional leading cardiac surgery centres in Canada and the United States. About Arch Biopartners Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury. Arch's development pipeline includes: * LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI. * Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI. * CKD Platform: next-generation therapeutics targeting chronic kidney disease. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide[1]. Both lead programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development. For more details about the Company's science and ongoing clinical trials, please visit: www.archbiopartners.com/our-science Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for scientific insights and industry news. The Company has 66,933,289 common shares outstanding. | Aaron Benson Director of Communications Arch Biopartners, Inc. 647-428-7031 | / | | / | / | Send a message or subscribe for trial updates and company news at www.archbiopartners.com/contact-us Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of the Company's future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates targeting chronic kidney disease and the dipeptidase-1 (DPEP-1) pathway, including the outcome of its clinical trials relating to LSALT peptide (Metablok) or cilastatin, the successful commercialization and marketing of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio. These statements are based on management's current expectations and beliefs, including certain factors and assumptions, as described in the Company's most recent annual audited financial statements and related management discussion and analysis under the heading "Business Risks and Uncertainties". As a result of these risks and uncertainties, or other unknown risks and uncertainties, the actual results may differ materially from those contained in any forward-looking statements. The words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company undertakes no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including the Company's most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval ("SEDAR") website at www.sedarplus.ca. References: * Mark, Patrick B et al. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet, 2025;406(10518), 2461 - 2482. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01853-7/fulltext The scientific and medical content of this release has been reviewed and approved by the Company's Chief Science Officer. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Faq. What does the Clinical Trial Agreement with Fraser Health mean for Arch Biopartners (ACHFF)? It enables Royal Columbian Hospital to prepare for patient recruitment in the Phase II CS-AKI trial. According to the company, RCH now has final Research Ethics Board and operational approvals plus a letter of authorization from Fraser Health, supporting site activation. How many sites are active in Arch Biopartners' (ACHFF) Phase II LSALT CS-AKI trial after Royal Columbian Hospital activation? Royal Columbian Hospital is the ninth site activated globally in the study. According to the company, RCH is also the fourth site in Canada to reach activation and prepare for recruitment. Which Canadian hospitals are currently recruiting for Arch Biopartners' (ACHFF) Phase II CS-AKI trial? Toronto General Hospital, St. Michael's Hospital, University of Calgary, and now Royal Columbian Hospital are recruiting. According to the company, those four Canadian centres are actively enrolling new patients into the trial. What approvals did Royal Columbian Hospital receive to start recruitment for the ACHFF Phase II trial? RCH received final Research Ethics Board and operational approvals plus a letter of authorization from Fraser Health. According to the company, these approvals complete site readiness for recruitment and study start-up activities. Will Arch Biopartners (ACHFF) add more sites in Canada and the US for the Phase II CS-AKI trial? The company is progressing feasibility and start-up discussions with additional cardiac surgery centres in Canada and the United States. According to the company, those discussions aim to expand site activation beyond the current nine global sites.

Black Press Media
Mar 14th, 2026
$1.3M funding will help more Indigenous elders in Chilliwack with at-home care

$1.3M funding will help more Indigenous elders in Chilliwack with at-home care. Published 8:45 am Saturday, March 14, 2026 An at-home program that offers care to Indigenous elders in the Fraser Valley will be expanding, with the main focus on Chilliwack, thanks to $1.3 million in new funding. The Indigenous Caregiver Support Model (ICSM) is a home-based program that supports elders with "complex needs to age safely at home and in their community," according to a Fraser Health press release. It is one of five programs in B.C. benefitting from a total of $6.3 million in funding from Health Research BC over the next three years. The funding will advance research to help B.C. seniors age comfortably in their own home. The ICSM program was launched in 2023 as a pilot project and has supported 33 elders and their caregivers in the Eastern Fraser Valley, including Chilliwack. Its aim is to reduce caregiver strain and improve elder wellbeing by providing culturally safe, coordinated in-home support, training, and financial assistance for Indigenous families caring for elders. It is co-designed by Fraser Health Indigenous Health, Stó:lō Service Agency, First Nations Health Authority, and Métis Nation British Columbia. "This model is an example of what is possible when care is built on relationships, trust and community," said Amanda LaBoucane, interim vice president, Indigenous Health and Cultural Safety. "Many elders and caregivers in the Chilliwack area have experienced firsthand the impacts of residential schools and the child welfare system. By strengthening caregiver capacity and confidence while bridging into integrated clinical care teams run by and for Indigenous people, we see improved health and wellness and stronger relationships within and between communities." The program is currently operating in the Fraser Valley, including Chilliwack, but the expansion will focus on urban Chilliwack as that is an identified need, said Carrie Stefanson with Fraser Health. Caregivers receive skills training and an honorarium to help reduce the economic strain of caregiving, while elders receive regular home visits from Indigenous-led clinical teams who provide culturally safe, relationship-based care, rooted in trust, kindness and respect, according to a Fraser Health.

Fraser Health
Sep 12th, 2024
Leveraging artificial intelligence to assist with scheduling

Fraser Health has partnered with Deloitte Canada to develop and launch scheduling tools that leverage artificial intelligence (AI) and machine-learning solutions to accurately forecast the waves in demand Fraserhealth see in the health system.

Government of British Columbia
Aug 22nd, 2024
Permanent supportive, complex-care homes open in Fraser Valley

For people not already connected to services, Fraser Health will work in partnership with Coast Mental Health to provide on-site clinical supports, including services from a psychiatric nurse, community nurse, licensed practical nurse, social worker and traditional wellness practitioners.

Daily Hive
Sep 12th, 2023
Construction begins on Surrey's new $2.9 billion Cloverdale hospital

Through a procurement process, Fraser Health has selected Ellis-Don Design Build to design and build the new facility through a design-build agreement.